article thumbnail

Financing extension for small molecule neoantigen immuno-oncology company 

Drug Discovery World

The company is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (MMR) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore has announced a further extension of £9.6 million (approximately $12.2 million).

article thumbnail

Redirecting the pioneering function of FOXA1 with covalent small molecules

Covalent Modifiers

Here, we report the chemical proteomic discovery of electrophilic small molecules that stereoselectively and site-specifically bind the pioneer TF, FOXA1, at a cysteine (C258) within the forkhead DNA-binding domain. Chemical probes are lacking for pioneer TFs, which has hindered their mechanistic investigation in cells.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A phenotypic screen with Trypanosoma brucei for discovering small molecules that target the SLiM?binding pocket of proliferating cell nuclear antigen orthologs

Chemical Biology and Drug Design

Abstract Proliferating cell nuclear antigen (PCNA) is a homo-trimeric protein complex that clamps around DNA to tether DNA polymerases to the template during replication and serves as a hub for many other interacting proteins. The assay design is to discover bioactive small molecules that restore proliferation in T. brucei

article thumbnail

The untapped potential of the transcriptome  

Drug Discovery World

DDW’s Megan Thomas speaks to Khan about the work her team is doing to create the first map of the druggable transcriptome, which involves understanding RNA biology to discover small molecule drugs. Understanding how RNA structure is linked to function would open up entirely new target space for the small molecule modality.

article thumbnail

A Guide to DNA Damage Response and Innate Immunity

Drug Target Review

There is extensive crosstalk between the DNA damage response (DDR) and innate immune pathways. Both are a focus for exciting new small-molecule drug therapeutics that target cancers and autoimmune disorders.

DNA 104
article thumbnail

Immuno-oncology collaboration to develop new type of cancer drug

Drug Discovery World

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Image: Human breast cancer cells stained for DNA (red). New treatments aim to take advantage in cancer cells’ DNA repair mechanisms.

article thumbnail

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. Many scientists are now discovering that this junk DNA plays an essential role in our biology and the epigenetic processes that respond to the environment to drive disease.

RNA 130